Technical Analysis for AMPE - Ampio Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 0.646 5.02% 0.03
AMPE closed up 5.02 percent on Wednesday, February 26, 2020, on 72 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Mar 17
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical AMPE trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
New Uptrend Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Fell Below 50 DMA Bearish 5.02%
180 Bearish Setup Bearish Swing Setup 5.02%
Lower Bollinger Band Walk Weakness 5.02%
Below Lower BB Weakness 5.02%
Down 3 Days in a Row Weakness 5.02%
Lower Bollinger Band Touch Weakness 5.02%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction. Its products include Ampion, a non-steroidal anti-inflammatory biologic to treat inflammatory conditions and autoimmune diseases; Optina, an orally administered danazol for the treatment of diabetic macular edema; Vasaloc for the treatment of diabetic nephropathy; and Zertane, an oral drug for treating male sexual dysfunction to premature ejaculation, which is under Phase III clinical trial. The company is also developing a handheld oxidation-reduction potential diagnostic device for use at home or in healthcare facilities that will measure the oxidants/antioxidant balances in human blood and plasma; and methylphenidate derivatives for cancer, which are in pre-clinical development. Ampio Pharmaceuticals, Inc. is headquartered in Greenwood Village, Colorado.
Health Biopharmaceutical Cancer Life Sciences Diabetes Autoimmune Diseases Healthcare Facilities Diagnostic Products Kidney Diseases Diabetic Nephropathy Diabetic Retinopathy Macular Edema Kidney Disease Metabolic Disorders Diabetic Macular Edema Eye Diseases

Is AMPE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.31
52 Week Low 0.26
Average Volume 1,226,849
200-Day Moving Average 0.50
50-Day Moving Average 0.62
20-Day Moving Average 0.68
10-Day Moving Average 0.66
Average True Range 0.05
ADX 34.53
+DI 20.31
-DI 19.47
Chandelier Exit (Long, 3 ATRs ) 0.61
Chandelier Exit (Short, 3 ATRs ) 0.76
Upper Bollinger Band 0.73
Lower Bollinger Band 0.62
Percent B (%b) 0.22
BandWidth 16.06
MACD Line 0.00
MACD Signal Line 0.01
MACD Histogram -0.011
Fundamentals Value
Market Cap 44.08 Million
Num Shares 68.2 Million
EPS -0.21
Price-to-Earnings (P/E) Ratio -3.08
Price-to-Sales 0.00
Price-to-Book 19.82
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.71
Resistance 3 (R3) 0.71 0.68 0.70
Resistance 2 (R2) 0.68 0.67 0.69 0.69
Resistance 1 (R1) 0.67 0.66 0.65 0.67 0.69
Pivot Point 0.64 0.64 0.64 0.64 0.64
Support 1 (S1) 0.62 0.63 0.61 0.63 0.60
Support 2 (S2) 0.60 0.62 0.60 0.60
Support 3 (S3) 0.58 0.60 0.59
Support 4 (S4) 0.58